Ginkgo Bioworks Holdings Inc (DNA) Stock AnalysisDNAGinkgo Bioworks Holdings Inc

Ginkgo Bioworks Holdings, Inc. offers biological research and development (R&D) services on its platform and autonomous laboratory to enable its customers to bring their products to market. The Company sells tools and biological R&D services across a range of industries to government and commercial customers. Its in-house autonomous lab is available as Cloud Lab through its Datapoints and Solutions contract research services. Its single segment, namely cell engineering, provides tools and biological R&D services across a range of industries. Its cell engineering customers work with biology to discover and manufacture new products across industries such as medicine, agriculture, industrial biotechnology and government. It provides R&D services spanning genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics. It provides a suite of microservices for product developers across industries that support bioengineers with protein engineering. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Ginkgo Bioworks Holdings Inc is currently trading at $13, which is above the analyst's price target of $9. The stock has shown a significant 20-day change of +92.59%, indicating strong recent momentum. However, the company reported a Q2 loss with a GAAP EPS of -$0.92 and a revenue decline of 48.7% year-over-year, raising concerns about its financial stability. Additionally, insider selling has increased by 74248.78%, suggesting a lack of confidence from company insiders. Given these factors, while the recent price action is positive, the underlying financial challenges and insider selling signal caution for long-term investors.

2 analysts cover DNA: 0 rate it Buy, 0 Hold and 2 Sell. The average price target is 12.00.